V

Virax Biolabs Group Ltd
NASDAQ:VRAX

Watchlist Manager
Virax Biolabs Group Ltd
NASDAQ:VRAX
Watchlist
Price: 0.28 USD 1.08% Market Closed
Market Cap: $1.8m

Net Margin

-188 120%
Current
Declining
by 126 690.5%
vs 3-y average of -61 429.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-188 120%
=
Net Income
$-5.6m
/
Revenue
$3k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-188 120%
=
Net Income
$-5.6m
/
Revenue
$3k

Peer Comparison

Country Company Market Cap Net
Margin
UK
Virax Biolabs Group Ltd
NASDAQ:VRAX
1.8m USD
Loading...
US
Mckesson Corp
NYSE:MCK
102.3B USD
Loading...
US
Cencora Inc
NYSE:COR
67.7B USD
Loading...
US
Amerisourcebergen Corp
LSE:0HF3
67.7B USD
Loading...
US
Cardinal Health Inc
NYSE:CAH
50B USD
Loading...
AU
Sigma Healthcare Ltd
ASX:SIG
35.5B AUD
Loading...
CN
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
64.2B CNY
Loading...
CN
Huadong Medicine Co Ltd
SZSE:000963
63.6B CNY
Loading...
US
Henry Schein Inc
NASDAQ:HSIC
8.9B USD
Loading...
KR
Celltrion Healthcare Co Ltd
KOSDAQ:091990
12.2T KRW
Loading...
CN
Sinopharm Group Co Ltd
HKEX:1099
66B HKD
Loading...

Market Distribution

Lower than 100% of companies in United Kingdom
Percentile
0th
Based on 3 670 companies
0th percentile
-188 120%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Virax Biolabs Group Ltd
Glance View

Market Cap
1.8m USD
Industry
Health Care

Virax Biolabs Group Ltd is a GB-based company operating in Health Care Providers & Services industry. Virax Biolabs Group Limited is a biotechnology company. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and med-tech and personal protective equipment (PPE) products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear, ViraxCare, and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Its products include antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. ViraxCare develops and distributes advanced medical devices, technology, and PPE globally. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus.

VRAX Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-188 120%
=
Net Income
$-5.6m
/
Revenue
$3k
What is Virax Biolabs Group Ltd's current Net Margin?

The current Net Margin for Virax Biolabs Group Ltd is -188 120%, which is below its 3-year median of -61 429.5%.

How has Net Margin changed over time?

Over the last 2 years, Virax Biolabs Group Ltd’s Net Margin has decreased from -63 459.3% to -188 120%. During this period, it reached a low of -188 120% on Sep 30, 2025 and a high of -4 305.3% on Mar 31, 2024.

Back to Top